Total Payments
$35,807
2024 Payments
$11,421
Companies
12
Transactions
61
Medicare Patients
4,062
Medicare Billing
$490,493
Payment Breakdown by Category
Consulting$22,208 (62.0%)
Other$6,500 (18.2%)
Travel$3,832 (10.7%)
Food & Beverage$2,885 (8.1%)
Research$300.00 (0.8%)
Education$75.08 (0.2%)
Gifts$6.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $22,208 | 7 | 62.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $6,500 | 1 | 18.2% |
| Travel and Lodging | $3,832 | 16 | 10.7% |
| Food and Beverage | $2,885 | 33 | 8.1% |
| Unspecified | $300.00 | 1 | 0.8% |
| Education | $75.08 | 2 | 0.2% |
| Gift | $6.96 | 1 | 0.0% |
Payments by Type
General
$35,507
60 transactions
Research
$300.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $23,137 | 13 | $0 (2024) |
| Baxter Healthcare | $8,833 | 32 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,834 | 5 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $1,000 | 1 | $0 (2021) |
| Medtronic, Inc. | $300.00 | 1 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $165.97 | 2 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $157.48 | 2 | $0 (2017) |
| Ardelyx, Inc. | $138.79 | 1 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $120.59 | 1 | $0 (2019) |
| Amgen Inc. | $93.58 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,421 | 10 | Novo Nordisk Inc ($11,042) |
| 2023 | $208.22 | 2 | Bayer Healthcare Pharmaceuticals Inc. ($117.00) |
| 2022 | $9,218 | 8 | Novo Nordisk Inc ($9,016) |
| 2021 | $5,505 | 3 | Novo Nordisk Inc ($3,080) |
| 2019 | $7,504 | 18 | BAXTER HEALTHCARE ($6,917) |
| 2018 | $1,770 | 17 | BAXTER HEALTHCARE ($1,611) |
| 2017 | $180.68 | 3 | Alexion Pharmaceuticals, Inc. ($157.48) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $124.46 | General |
| Category: Cardio-renal | ||||||
| 06/24/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $8,662.50 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $756.20 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $467.78 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $357.76 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $347.33 | General |
| 06/23/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 05/01/2024 | Baxter Healthcare | — | Food and Beverage | In-kind items and services | $113.30 | General |
| 03/15/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 01/24/2024 | Ardelyx, Inc. | XPHOZAH 30 MG (Drug) | Food and Beverage | In-kind items and services | $138.79 | General |
| Category: NEPHROLOGY | ||||||
| 04/05/2023 | Baxter Healthcare | — | Food and Beverage | In-kind items and services | $91.22 | General |
| Category: Surgical Care | ||||||
| 03/10/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $117.00 | General |
| Category: Cardio-renal | ||||||
| 12/01/2022 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 12/01/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $515.26 | General |
| 12/01/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $461.40 | General |
| 12/01/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $252.64 | General |
| 12/01/2022 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $196.30 | General |
| 11/30/2022 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $880.00 | General |
| 04/08/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $102.11 | General |
| Category: Cardio-renal | ||||||
| 04/06/2022 | Baxter Healthcare | Renal - PD (Device) | Food and Beverage | In-kind items and services | $99.97 | General |
| Category: Renal | ||||||
| 12/02/2021 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $3,080.00 | General |
| 11/17/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| Category: Cardio-renal | ||||||
| 08/31/2021 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/01/2019 | BAXTER HEALTHCARE | Renal - Non Product Related (Biological) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $6,500.00 | General |
| Category: Renal | ||||||
| 10/05/2019 | BAXTER HEALTHCARE | Non-Franchise (NOF) - NonProduct (Biological) | Food and Beverage | In-kind items and services | $34.16 | General |
| Category: Fluid Systems | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 333 | 723 | $322,385 | $87,320 |
| 2022 | 27 | 1,213 | 2,081 | $458,714 | $121,677 |
| 2021 | 32 | 1,363 | 2,230 | $554,242 | $152,988 |
| 2020 | 26 | 1,153 | 1,923 | $483,812 | $128,509 |
Total Patients
4,062
Total Services
6,957
Medicare Billing
$490,493
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 104 | 202 | $67,670 | $23,025 | 34.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 12 | 68 | $80,444 | $20,141 | 25.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 79 | 216 | $59,616 | $13,023 | 21.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 13 | 39 | $38,298 | $9,764 | 25.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 52 | 57 | $33,117 | $8,370 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 61 | $18,483 | $6,146 | 33.3% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 15 | 49 | $13,524 | $3,579 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $6,084 | $1,702 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 19 | $5,149 | $1,571 | 30.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 17 | 97 | $114,751 | $30,162 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 95 | 179 | $78,760 | $27,236 | 34.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 99 | 273 | $75,348 | $16,970 | 22.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 56 | 60 | $34,860 | $10,131 | 29.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 101 | $30,603 | $8,766 | 28.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 14 | 32 | $31,424 | $8,271 | 26.3% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 14 | 67 | $18,492 | $5,039 | 27.2% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2022 | 70 | 95 | $16,815 | $3,872 | 23.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $5,135 | $1,499 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 15 | $4,590 | $1,364 | 29.7% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 67 | 103 | $9,991 | $1,361 | 13.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 64 | 101 | $4,545 | $1,052 | 23.2% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 76 | 124 | $3,472 | $791.99 | 22.8% |
| 82043 | Urine microalbumin (protein) level | Office | 2022 | 86 | 139 | $8,896 | $786.91 | 8.8% |
| 82306 | Vitamin d-3 level | Office | 2022 | 26 | 26 | $3,250 | $761.90 | 23.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2022 | 86 | 139 | $3,753 | $705.95 | 18.8% |
About Dr. Mark Williams, MD
Dr. Mark Williams, MD is a Specialist healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184653891.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Williams, MD has received a total of $35,807 in payments from pharmaceutical and medical device companies, with $11,421 received in 2024. These payments were reported across 61 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($22,208).
As a Medicare-enrolled provider, Williams has provided services to 4,062 Medicare beneficiaries, totaling 6,957 services with total Medicare billing of $490,493. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Nephrology
- Location Boston, MA
- Active Since 07/03/2006
- Last Updated 04/25/2011
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1184653891
Products in Payments
- Renal - Non Product Related (Biological) $6,566
- Kerendia (Drug) $1,769
- Renal - Acute (Device) $1,675
- Velphoro (Drug) $1,000
- Non-Franchise (NOF) - NonProduct (Biological) $287.30
- LOKELMA (Drug) $165.97
- SOLIRIS (Drug) $157.48
- XPHOZAH 30 MG (Drug) $138.79
- AURYXIA (Drug) $120.59
- Renal - PD (Device) $99.97
- Parsabiv (Biological) $93.58
- Non-Covered $65.60
- Veltassa (Drug) $23.20
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Boston
Keith Flaherty, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M
Dr. Caroline Baumal, Md, MD
Specialist — Payments: $988,075
Specialist $988,075
Dr. Paul Zei, M.d., Ph.d, M.D., PH.D
Specialist — Payments: $768,186
Specialist $768,186
Dr. Aman Patel, M.d, M.D
Specialist — Payments: $712,473
Specialist $712,473
Dr. Steven Treon, Md, Phd, MD, PHD
Specialist — Payments: $464,440
Specialist $464,440
Dr. Adam Rogers, M.d, M.D
Specialist — Payments: $316,568
Specialist $316,568